NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.
NeuroDerm CEO to Present at Upcoming Investor Conferences
CEO Oded S. Lieberman will present at the Jefferies Autumn 2015 Global Healthcare Conference in London and at the Oppenheimer 26th Annual Healthcare Conference taking place in New York. ”> Read More
NeuroDerm Announces Third Quarter 2015 Financial Results
Company to Host Conference Call and Webcast Today at 8:30 a.m. ET. > Read More
NeuroDerm Announces Streamlined U.S. Development Plan Following FDA Feedback on ND0612H and ND0612L for the Treatment of Parkinson’s Disease
Based on FDA input, NeuroDerm is not required to conduct its largest Phase III pivotal trial of 360 patients .”> Read More